Valeant's Papa Lays Out Plan For Turnaround
Executive Summary
The beleaguered spec pharma's new CEO set the tenor for the company going forward as he laid out plans for a turnaround during a first quarter call.
You may also be interested in...
OTC Naloxone Pioneer Emergent BioSolutions Puts Papa At Helm As It Navigates Strategy Shift
Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.
Rumor Has It: Expect Valeant Divestitures?
The plagued specialty pharma has been rumored to have at least one suitor, but analysts are skeptical and expect multiple divestitures will be required if the company is going to gain back some of its losses.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.